Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Calidi Biotherapeutics, a biotechnology firm focused on targeted genetic medicines, announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference. The company will present its RedTail platform and lead candidate CLD-401, aimed at treating metastatic cancers, particularly non-small cell lung cancer and head and neck can…
Avalyn Pharma announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference with a fireside chat presentation. The company is advancing inhaled formulations of antifibrotic medicines aimed at improving treatment for serious respiratory diseases such as pulmonary fibrosis. Avalyn is currently conducting Phase 2 trials fo…
MiMedx Group, Inc., a leader in wound care and healing solutions, announced that its senior management will participate in the Cantor Global Healthcare Conference and the Lake Street BIG10 Best Ideas Growth Conference to engage with investors and discuss company developments.
Anavex Life Sciences Corp., a Nasdaq-listed clinical-stage biopharmaceutical company focused on central nervous system diseases, announced an investor call to be held on September 9, 2026. The call, led by Interim CEO Terrie Kellmeyer, Ph.D., will outline the company's clinical development strategy and priorities. The announcement follows Anavex's …
Amwell (NYSE: AMWL) announced that the Department of Veterans Affairs (VA) has issued a Letter of Intent to deploy Amwell's virtual health platform across the VA enterprise to modernize its digital health infrastructure. The VA's selection follows a comprehensive evaluation highlighting Amwell's scalable video consultation capabilities, interoperab…
BioAge Labs has dosed the first participant in its Phase 2 QUELL-DME trial, evaluating the novel oral NLRP3 inhibitor BGE-102 for diabetic macular edema treatment. The trial, involving approximately 180 participants, assesses BGE-102 as monotherapy and in combination with anti-VEGF therapy, targeting improvements in visual acuity with topline resul…
MBX Biosciences, a Nasdaq-listed clinical-stage biopharmaceutical company, announced the appointment of Jeff Held as Chief Legal Officer. Held brings over 30 years of legal and executive experience in biotechnology and healthcare, having played key roles in financing, licensing, and company scale-ups. His leadership is expected to aid MBX's advance…
Canadian equity futures pointed to a weaker open as fresh U.S. trade rhetoric pressured sentiment and commodity and financial sectors showed weakness. Bombardier Inc. is under market pressure after a U.S. presidential threat to bar its aircraft from the American market unless production is moved to the United States, a move that could imperil rough…
Citi upgraded Nordex SE from neutral to buy and raised its price target to €50, citing stronger-than-expected margin momentum and positive auction volume signals that underpin higher EBITDA and order forecasts. The broker also increased multi-year EBITDA estimates and raised the 2027 EV/EBITA multiple, while flagging specific execution and auction …
A federal judge has ordered the administration to provide at least 48 hours' notice before engaging in any activity at the site of a proposed 250-foot (76-meter) triumphal arch near Arlington National Cemetery, with an exception for narrowly defined archaeological investigations under the National Historic Preservation Act. The decision follows the…
Dyne Therapeutics announced that it will present additional one-year clinical data from its Phase 1/2 ACHIEVE trial studying z-basivarsen (DYNE-101) for treating Myotonic Dystrophy Type 1 (DM1) at two major upcoming neuromuscular medical meetings. The data include pooled dose group results versus a natural history cohort and updated safety informat…
Affirm’s Q4 beat and the rapid ramp in card adoption (5.2M active cardholders; 19% attach) make the company’s Card Engine the most tangible pathway yet to sustainable, high-margin payments profit. Valuation (~$24.4B market cap; EPS $5.72) leaves room for multiple expansion if management hits its FY27 GMV > $64B and 30.5%+ adjusted operating margin …
Shares of Solaris Oilfield Infrastructure rose sharply in pre-market trading after management issued a guidance update that meaningfully increased adjusted EBITDA expectations for the remainder of 2026 and set an initial outlook for early 2027. The company cited stronger-than-expected power services performance and contributions from recent acquisi…
Oportun, a Nasdaq-listed financial services firm, announced the appointment of Bill Franklin as Chief Financial Officer. Franklin brings over 20 years of experience in financial leadership, including key roles at Discover Financial Services. His expertise is expected to drive Oportun's financial strategy and support its mission of empowering member…
AGM Group Holdings Inc. and HashBeaver have partnered to develop a desktop decentralized physical infrastructure network (DePIN) node that leverages ASIC technology for Bitcoin mining and incorporates AI-assisted management features. This device seeks to transform traditional Bitcoin miners into multifunctional personal computing terminals capable …
3 E Network Technology Group Limited outlined its full-stack AI storage strategy focusing on enterprise memory and storage modules, proprietary SSD development, and all-flash storage servers. This initiative aims to address growing data throughput demands in AI with integrated hardware solutions, support its global AI data center expansion, and exp…
Solaris Energy Infrastructure (NYSE: SEI) reported raised Adjusted EBITDA guidance for the third and fourth quarters of 2026 and provided an initial projection for the first quarter of 2027. The stock climbed about 6% on the news as the company cited stronger contributions from core power services and better-than-expected results from recently acqu…
GE Aerospace agreed to acquire Consolidated Precision Products from Warburg Pincus and Berkshire Partners for $11.75 billion. The Cleveland-based castings and sub-assemblies manufacturer, a long-time GE supplier with about 6,600 employees across more than 20 facilities, will be combined with GE Aerospace operations to expand capacity and accelerate…
Intel shares rose sharply in pre-market trade after supply-chain sources reported the company will raise PC CPU prices by about 10% in early October, part of a broader pricing strategy to improve gross margins. The move coincided with an analyst upgrade from Northland and a manufacturing milestone for Intel Foundry using High NA EUV lithography, cr…
Inhibrx Biosciences saw its stock climb after the company disclosed positive Phase 2 results from the HexAgon study evaluating INBRX-106 in combination with pembrolizumab for first-line, PD-L1 positive metastatic or unresectable recurrent head and neck squamous cell carcinoma. The combo produced higher confirmed objective response and six-month pro…
Rigetti Computing's stock jumped in pre-market trading after the company finalized a $100 million CHIPS Act award from the U.S. Department of Commerce. The binding agreement, executed through a Rigetti subsidiary, funds three R&D initiatives aimed at overcoming scaling bottlenecks in superconducting quantum hardware and includes a minority, non-con…
Airbnb shares climbed 0.6% in pre-market trading after Raymond James elevated the stock from Market Perform to Outperform and assigned a $200 price target, citing an "AI Founder Mode" thesis. The upgrade, paired with CEO Brian Chesky's scheduled presentation at the Goldman Sachs Communacopia + Technology Conference, and solid Q2 2026 results are ci…
Clearmind Medicine Inc. announced Yale University's IRB approval to initiate patient recruitment for Parts B and C of its Phase I/II clinical trial evaluating CMND-100, a non-hallucinogenic psychedelic-derived drug candidate targeting Alcohol Use Disorder. This milestone follows positive safety results from Part A, allowing accelerated enrollment a…
Morgan Stanley downgraded Peloton to Underweight from Equal Weight, with analyst Nathan Feather cutting his price target to $4.50 and reducing fiscal 2027 and 2028 estimates. Feather highlighted a marked contraction at the top of the funnel, steep declines in gross additions and falling connected fitness subscriber growth in fiscal 2026. He pointed…
Peloton stock fell sharply in pre-market trading after Morgan Stanley downgraded the company and cut its price target, while UBS trimmed earnings estimates and lowered its target. Analysts cited sustained weakness in subscriber growth and collapsing customer additions. Concurrent insider selling and a lack of offsetting market support contributed t…
